Denali Therapeutics Inc (DNLI) - Total Liabilities

Latest as of March 2026: $339.93 Million USD

Based on the latest financial reports, Denali Therapeutics Inc (DNLI) has total liabilities worth $339.93 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Denali Therapeutics Inc (DNLI) equity growth momentum to track the company's year-over-year net asset growth rate.

Denali Therapeutics Inc - Total Liabilities Trend (2015–2025)

This chart illustrates how Denali Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See DNLI free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Denali Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Denali Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
PT Trimegah Bangun Persada Tbk JK:NCKL	Indonesia	Rp15.20 Trillion
Berner Kantonalbank AG SW:BEKN	Switzerland	CHF39.89 Billion
Chenzhou Jingui Silver Industry Co Ltd SHE:002716	China	CN¥3.35 Billion
Zhejiang Wanfeng Auto Wheel Co Ltd SHE:002085	China	CN¥8.18 Billion
BW LPG Limited NYSE:BWLP	USA	$1.32 Billion
Huhtamaki Oyj HE:HUH1V	Finland	€2.64 Billion
Schneider National Inc NYSE:SNDR	USA	$1.96 Billion
Nordic Semiconductor ASA OL:NOD	Norway	Nkr328.31 Million

Liability Composition Analysis (2015–2025)

This chart breaks down Denali Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Denali Therapeutics Inc (DNLI) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	9.28	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.37	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.27	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Denali Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Denali Therapeutics Inc (2015–2025)

The table below shows the annual total liabilities of Denali Therapeutics Inc from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	$131.09 Million	-9.28%
2024-12-31	$144.50 Million	+17.51%
2023-12-31	$122.96 Million	-70.57%
2022-12-31	$417.81 Million	-5.44%
2021-12-31	$441.87 Million	-2.62%
2020-12-31	$453.75 Million	+186.56%
2019-12-31	$158.34 Million	+37.52%
2018-12-31	$115.14 Million	+450.25%
2017-12-31	$20.93 Million	+26.45%
2016-12-31	$16.55 Million	-68.37%
2015-12-31	$52.32 Million	--

About Denali Therapeutics Inc

NASDAQ:DNLI USA Biotechnology

Market Cap

$3.65 Billion

Market Cap Rank

#4578 Global

#1568 in USA

Share Price

$23.02

Change (1 day)

-5.46%

52-Week Range

$12.75 - $27.21

All Time High

$93.56